Burgdorf et al1 reminded me of the time of my dermatology residency, when the person’s name given to the variant of the pharmacotherapy formulation or the physical treatment (Goeckerman treatment or the Ingram regimen of light therapy) was required knowledge for an upcoming dermatologist and a guarantee of quality and therapeutic success.
Therefore, I am honored to add to the list of topical treatments Kligman’s ointment or formula, a compounded formulation that consists of hydroquinone, 5%; tretinoin, 0.1%; and dexamethasone, 0.1%, in hydrophilic ointment.2 The formulation was developed by Albert Montgomery Kligman, MD (1916-2010), from the University of Pennsylvania, Philadelphia, a prominent and controversial academic, practicing dermatologist. The compounded formulation is still used to treat melasma, ephelides, and postinflammatory hyperpigmentation. As the authors noted in their original publication, depigmentation cannot be attained when any one of the components is omitted.2
Zouboulis CC. Albert Montgomery Kligman—Remembering a Pioneer of Topical Treatment. JAMA Dermatol. 2017;153(1):65. doi:10.1001/jamadermatol.2016.0127
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: